Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 19/20 | 1.00 |
| ▸ | MAOB | P27338 | 8/20 | 1.00 |
| ▸ | MAOA | P21397 | 3/20 | 0.71 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.71 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.71 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.66 |
| ▸ | HTR1B | P28222 | 1/20 | 0.66 |
| ▸ | HTR2A | P28223 | 1/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14880427 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL18214503 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL19409816 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL14880428 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL19422223 | 0.86 | KDM1A (0.76) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL900481 | 0.84 | KDM1A (0.72) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| Iadademstat SCHEMBL19428614 | 0.83 | KDM1A (1.00) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| Iadademstat SCHEMBL16010213 | 0.83 | KDM1A (1.00) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| Iadademstat SCHEMBL20260493 | 0.83 | KDM1A (1.00) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| Iadademstat SCHEMBL19409823 | 0.83 | KDM1A (1.00) | KDM1AMAOBMAOAKDM1BRCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190256929-A1 | PHARMACODYNAMIC BIOMARKERS FOR PERSONALIZED CANCER CARE USING EPIGENETIC MODIFYING AGENTS | ORYZON GENOMICS SA (ES) | 2019-08-22 | — | — | US | disclosed |
| US-20190153538-A1 | GENE EXPRESSION BIOMARKERS FOR PERSONALIZED CANCER CARE TO EPIGENETIC MODIFYING AGENTS | ORYZON GENOMICS SA (ES) | 2019-05-23 | — | — | US | disclosed |
| US-10265279-B2 | Combinations of LSD1 inhibitors for use in the treatment of solid tumors | ORYZON GENOMICS, S.A. (ES) | 2019-04-23 | — | — | US | disclosed |
| US-20180079709-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2018-03-22 | — | — | US | disclosed |
| US-20170281567-A1 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS | HOFFMANN-LA ROCHE INC. (US) | 2017-10-05 | — | — | US | disclosed |
| WO-2017157825-A1 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-09-21 | — | — | WO | disclosed |
| US-9670136-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS S.A. (ES) | 2017-06-06 | — | — | US | disclosed |
| WO-2017060319-A1 | GENE EXPRESSION BIOMARKERS FOR PERSONALIZED CANCER CARE TO EPIGENETIC MODIFYING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-04-13 | — | — | WO | disclosed |
| US-20160368857-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2016-12-22 | — | — | US | disclosed |
| US-9469597-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS S.A. (ES) | 2016-10-18 | — | — | US | disclosed |
| US-20150119396-A9 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2015-04-30 | — | — | US | disclosed |
| US-20140256729-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368857-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MAOB 147/4885MAOA 135/4885 |
| US-20150119396-A9 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1A, KDM1B, KDM3B | KDM1A 1/4885MAOB 186/4885MAOA 175/4885 |
| US-10265279-B2 | Combinations of LSD1 inhibitors for use in the treatment of solid tumors | KDM1B, DOT1L, KDM1A | KDM1A 3/4885MAOB 917/4885MAOA 696/4885 |
| US-20140256729-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1A, KDM1B, KDM3B | KDM1A 1/4885MAOB 186/4885MAOA 175/4885 |
| US-20170281567-A1 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS | KDM1B, DOT1L, KDM1A | KDM1A 3/4885MAOB 917/4885MAOA 696/4885 |
| US-20180079709-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MAOB 147/4885MAOA 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.